ICIs are one of the most promising therapeutic approaches, and various studies have demonstrated the initial efficacy of anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) monoclonal antibodies in BMs from lung cancer; however, there have also been contrasting results. Here, CD274 is linked to lung cancer.